根据名称进行药物检索

Aceon与低血压

Aceon与低血压安全配伍检测的结果。

检测结果:

Aceon <> 低血压

现实性: 23.07.2019 评论家: 医学副博士Shkutko P.M., in

通过权威的信息来源 Drugs.com、Rxlist.com、Webmd.com、Medscape.com，在进行所选药物与这种伴发疾病互相作用检测时，发现一些会产生负面影响或对身体危害的禁忌症及副作用。

用户:

高手抑制剂可能会导致对症低血压，大多数往往在开始治疗和患者的体积和/或钠贫或治疗充血性心力衰竭(瑞士法郎). 治疗与高手抑制剂应给予谨慎地在这些患者和那些易患血容量或低鈉血症国家(例如，病人的利尿剂治疗，尤其是如果这是最近制定的；这些关于食盐的限制；这些严重或长期腹泻或者呕吐；和肾透析的病人)。体积和/或钠损耗应予以纠正之前发起治疗与高手抑制剂，病人应该血流动力学稳定。如果伴随的利尿剂和/或膳食钠限制就业，减少或暂时扣缴的配量的利尿剂和/或自由化的饮食钠的摄入量为2至3天前可以帮助尽量减少风险的严重低血压患者都能够容忍这样的调整。高手抑制剂还应谨慎使用患者的人过大的低血压可能造成严重后果，例如患有冠状动脉或脑血管功能不全。患者风险过大的低血压应该发起高手抑制剂的治疗在很接近的医疗监督，并密切跟踪用于第一次2个星期的治疗并且每当剂量的王牌抑制剂或利尿增加。

来源

Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994): 358-64
Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992): 215-23
Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996): 658-70
Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989): 389-95
"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company, Whippany, NJ.
American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb, Princeton, NJ.
Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993): 577
Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992): 1426-32
"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc, Marietta, GA.
Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987): 529-36
Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994): 551-6
Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992): c137-9
"Product Information. Prinivil (lisinopril)." Merck & Co, Inc, West Point, PA.
Inman WH, Rawson NS, Wilton LV, et al "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988): 826-9
Cooper WD, Sheldon D, Brown D, et al "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987): 346-9
Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989): 837-8
Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994): 871-4
Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986): 539-40
"Product Information. Univasc (moexipril)." Schwarz Pharma, Mequon, WI.
Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994): 838-53
Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995): s11-6
"Product Information. Vasotec (enalapril)." Merck & Co, Inc, West Point, PA.
"Product Information. Lotensin (benazepril)." Ciba Pharmaceuticals, Summit, NJ.
Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996): 55-61
Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991): 511-39
Schoenberger JA, Testa M, Ross AD, et al "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990): 301-6
"Product Information. Accupril (quinapril)." Parke-Davis, Morris Plains, NJ.
"Product Information. Altace (ramipril)." Hoechst Marion-Roussel Inc, Kansas City, MO.
Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996): 1135
"Product Information. Capoten (captopril)." Bristol-Myers Squibb, Princeton, NJ.
MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991): iv33-7